Home
General Information to Patients
ALL
AML
Anus
Bladder/urothelial
Brain
Breast
Cervix
CLL
CML
Colon and Rectum
GIST
Hairy Cell Leuk.
Head and Neck
Hemato/Graft
Hepatic Ducts
Hodgkin
Kidney
Liver
Melanoma
Mesothelioma
MPN
MDS
Myeloma
Neuroendocr. T
NSCLC
NHL
Oesophagus
Ovary
Pancreas
Prostate
Sarcoma
Skin
SCLC
Solid Tumors
Stomach
Testis
Thyroid
Uterine Sarcoma
Uterus Lining
Clinical Trials
View all
Search
Videos for patients
Oral therapy
Chemo & Immunotherapy
Immunotherapy (professionals)
Guidelines : Management of Toxicities
Administration Guides and Advice to patients
Administrative Tools
Recherche
Home
Breast
Treatment Regimens
Breast
Breast
TREATMENT REGIMENS
Neoadjuvant and Adjuvant
Her2-
AC + Weekly Paclitaxel
AC + paclitaxel q 2 week (dose dense)
TC
AC
FEC (Bonneterre)
TAC
Capecitabine
Her2+
Docetaxel + carboplatin + trastuzumab (TC-H)
Paclitaxel + trastuzumab
Trastuzumab (adjuvant)
T-DM1 (adjuvant)
Hormonotherapy : Adjuvant and metastatic
Her2-
Ribociclib + letrozole
Palbociclib + letrozole
Palbociclib + fulvestrant
Abemaciclib +/- hormonotherapy
Évérolimus + exémestane
Anastrozole
Exemestane
Letrozole
Tamoxifen
Her2+
Metastatic
Her2+
Pertuzumab + trastuzumab + docetaxel
Pertuzumab + trastuzumab + paclitaxel
Tucatinib + trastuzumab + capécitabine
Trastuzumab déruxtécan
T-DM1 (trastuzumab emtansine)
Trastuzumab + weekly paclitaxel
Lapatinib + capecitabine
Her2-
Weekly paclitaxel (or q3 weeks)
Docetaxel q 3 wk
Doxorubicin
CMF IV q 3 weeks
CMF Standard (Bonnadonna) (per os)
Capecitabine
Eribulin
Vinorelbine
Nab-paclitaxel
Triples négatifs
Groupe d'étude en oncologie du Québec